Biologic agents do not up recurrent cancer risk in RA The Oncology Report The hazard ratios, adjusted for age and sex, for recurrent cancer were 0.55 for patients treated with drugs directed at tumor necrosis factor (TNF)-alpha and 0.47 for patients treated, off-label, with rituximab vs. nbDMARDs. However, Dr. Luca Silva ... |
